Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs

Nutrition and Cancer

Volumn 52, Issue 1, 2005, Pages 105-113

  Vine, Alex L ^a,b   Bertram, John S ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ASTAXANTHIN; BETA CAROTENE; BMS 453; BMS 493; CAROTENOID; CONNEXIN 43; LYCOPENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ANTAGONIST; RETINOID; RO 415253; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FIBROBLAST; GENE CONTROL; GENE EXPRESSION REGULATION; KERATINOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BENZOATES; BETA CAROTENE; CAROTENOIDS; CELL LINE; CONNEXIN 43; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; PPAR GAMMA; RECEPTORS, RETINOIC ACID; RETINOIDS; UP-REGULATION; XANTHOPHYLLS;

MURINAE;

EID: 24144467460     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5201_13     Document Type: Article

References (41)

1. King TJ, Fukushima LH, Hieber AD, Shimabukuro KA, Sakr A, et al.: Reduced levels of connexin 43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 21, 1097-1109, 2000.
2. Zhang L-X, Cooney RV, and Bertram JS: Carotenoids up-regulate connexin 43 gene expression independent of their pro-vitamin A or antioxidant properties. Cancer Res 52, 5707-5712, 1992.
3. Guo H, Acevedo P, Parsa DF, and Bertram JS: The gap-junctional protein connexin 43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids. J Invest Dermatol 99, 460-467, 1992.
4. Rogers M, Berestecky JM, Hossain MZ, Guo M, Kadle R, et al.: Retinoid-enhanced gap junctional communication is achieved by increased levels of connexin 43 mRNA and protein. Mol Carcinog 3, 335-343, 1990.
5. Mayne ST and Lippman S: Cancer prevention: Chemopreventive agents. Retinoids and carotenoids. In Principles and Practice of Oncology, DeVita, VT, Hellman S, and Rosenberg, SA (eds.). Philadelphia, PA: Lippencott-Raven, 1997, pp 585-599.
6. Zhang L-X, Cooney RV, and Bertram JS: Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer Chemopreventive action. Carcinogenesis 12, 2109-2114, 1991.
7. Hossain MZ, Wilkens LR, Mehta PP, Loewenstein WR, and Bertram JS: Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. Carcinogenesis 10, 1743-1748, 1989.
8. Matesic DF, Rupp HL, Bonney J, Ruch RJ, and Trosko JE: Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells. Mol Carcinog 10, 226-236, 1994.
9. King TJ, Fukushima L, and Bertram JS: Connexins and Carcinogenesis: upregulated expression of connexin43 by cancer preventive agents or by gene transfer decreases proliferation and expression of neoplasia. In Gap Junctions, Werner, R (ed.). Amsterdam: IOS Press, 1998, pp 357-361.
10. Vine AL and Bertram JS: Cancer chemoprevention by connexins. Cancer Metastasis Rev 21, 199-216, 2002.
11. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10, 940-954, 1996.
12. McEwan IJ: Gene regulation through chromatin remodelling by members of the nuclear receptor superfamily. Biochem Soc Trans 28, 369-373, 2000.
13. Vine AL, Leung YM, and Bertram JS: Transcriptional regulation of connexin 43 expression by retinoids and carotenoids: similarities and differences. Mol Carcinog 43, 75-85, 2005.
14. Teunissen BE, Jansen AT, van Amersfoorth SC, O'Brien TX, Jongsma HJ, et al.: Analysis of the rat connexin 43 proximal promoter in neonatal cardiomyocytes. Gene 322, 123-136, 2003.
15. Fernandez-Cobo M, Stewart D, Drujan D, and De Maio A: Promoter activity of the rat connexin 43 gene in NRK cells. J Cell Biochem 81, 514-522, 2001.
16. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, et al.: Transactivation via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif. Mol Endocrinol 15, 1677-1692, 2001.
17. Demmig-Adams B, Gilmore AM, and Adams WW: III, Carotenoids 3: in vivo function of carotenoids in higher plants. FASEB J 10, 403-412, 1996.
18. Tsuchihashi H, Kigoshi N, Iwatsuki M, and Niki E: Action of b-carotene as an antioxidant against lipid peroxidation. Arch Biochem Biophys 323, 137-147, 1995.
19. Paik J, During A, Harrison EH, Mendelsohn CL, Lai K, et al.: Expression and characterization of a murine enzyme able to cleave β-carotene-the formation of retinoids. J Biol Chem 276, 32160-32168, 2001.
20. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, et al.: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(κ)B kinase-dependent NF-κB activation. Mol Cells 16, 97-105, 2003.
21. Astorg P, Gradelet S, Leclerc J, Canivenc M-C, and Siess M-H: Effects of β-carotene and canthaxanthin on liver xenobiotic-metabolizing enzymes in the rat. Food Chem Toxic 32, 735-742, 1996.
22. Meyskens FL, Jr, Surwit E, Moon TE, Childers JM, Davis JR, et al.: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-frans-retinoic acid: A randomized trial. J Natl Cancer Inst 86, 539-543, 1994.
23. Hong WK, Lippman SM, Itri LM, Karp, DD, Lee JS, et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323, 795-801, 1990.
24. Mayne ST, Cartmel B, Baum M, Shor-Posner G, Fallon BG, et al.: Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res 61, 1457-1463, 2001.
25. Garewal HS, Katz RV, Meyskens FL, Pitcock J, Morse D, et al.: β-Carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg 125, 1305-1310, 1999.
26. Sakr W, Tabaska P, Kucuk O, and Bertram J S: Differential expression of connexin 43 in normal, preneoplastic and neoplastic squamous epithelium of the upper aerodigestive tract. Proc AACR 37, 269. 1996.
27. Cooney RV, Kappock TJ, Pung A, and Bertram JS: Solubilization, cellular uptake, and activity of β-carotene and other carotenoids as inhibitors of neoplastic transformation in cultured cells. Methods Enzymol 214, 55-68, 1993.
28. Keidel S, LeMotte P, and Apfel C. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Cell Biol 14, 287-298, 1994.
29. Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, et al.: Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat 56, 277-291, 1999.
30. Germain P, Iyer J, Zechel C, and Gronemeyer H: Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192, 2002.
31. Newcomer ME, Pappas RS, and Ong DE: X-ray crystallographic identification of a protein-binding site for both all-trans- and 9-cis-retinoic acid. Proc Natl Acad Sci U S A 90, 9223-9227, 1993.
32. Acevedo P and Bertram JS: Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells. Carcinogenesis 16, 2215-2222, 1995.
33. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, et al.: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650, 2002.
34. Harnisch M, Stahl W, Schulz WA, and Sies H: Induction of gap junctional communication by 4-oxoretinoic acid generated from its precursor canthaxanthin. Arch Biochem Biophys 317, 423-428, 1995.
35. Yang L, Ostrowski J, Reczek P, and Brown P: The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFβ and causing cell cycle arrest. Oncogene 20, 8025-8035, 2001.
36. Gibson DFC, Hossain MZ, Goldberg GS, Acevedo P, and Bertram JS: The mitogenic effects of transforming growth factor-B1 and 2 in 10T1/2 cells occur in the presence of enhanced gap junctional communication. Cell Growth Differ 5, 687-696, 1994.
37. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, et al.: Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 19, 2592-2601, 2000.
38. Mailfait S, Thoreau E, Belaiche D, and Formstecher BS: Critical role of the H6-H7 loop in the conformational adaptation of all-trans retinoic acid and synthetic retinoids within the ligand-binding site of RARalpha. J Mol Endocrinol 24, 353-364, 2000.
39. Newton DL, Henderson WR, and Sporn MB: Structure-activity relationships of retinoids in hamster tracheal organ culture. Cancer Res 40, 3413-3425, 1980.
40. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, et al.: Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 22, 5628-5634, 1994.
41. Stahl W, Hanusch M, and Sies H: 4-oxo-retinoic acid is generated from its precursor canthaxanthin and enhances gap junctional communication in 10T1/2 cells. Adv Exp Med Biol 387, 121-128, 1996.